AIM Urges Investigation into Vaccine Effects
Recently, a group of doctors affiliated with the Awaken India Movement (AIM) expressed significant concerns about the safety of the Covishield vaccine, which is manufactured by the Serum Institute of India. These concerns were voiced during a press conference, where the doctors urged the government to conduct a thorough review of the scientific data behind all COVID-19 vaccines. They also called for audits of the commercialization process and emphasized the need for an active surveillance and monitoring mechanism to promptly identify any vaccine adverse events.
Dr. Tarun Kothari, a radiologist and activist, stated that the government has not appropriately handled the rising number of reported deaths following COVID-19 immunization. He questioned the advertising of Covid vaccinations as “safe and effective” without enough scientific research.
One of the specific concerns raised was about Thrombosis with Thrombocytopenia Syndrome (TTS), a recognized adverse effect of several Covid vaccinations. Dr. Sujata Mittal, a gynaecologist and oncologist, stated that the Covid-19 vaccinations were administered without comprehensive phase-3 study data on probable adverse effects or mortality.
The AIM has been actively documenting occurrences of adverse events associated with COVID-19 vaccinations since the immunization program began in 2021. Despite their efforts, they claim that the government has not responded adequately to investigate these cases.
The doctors also called for compensation for vaccine victims and their families, suggesting the involvement of vaccine manufacturers in such compensation mechanisms. They proposed the establishment of fast-track and vaccine courts to ensure swift justice for those affected.
In response to worldwide concerns over the AstraZeneca vaccine, known as Covishield in India, AstraZeneca has launched a global withdrawal since improved vaccinations have become available since the pandemic began. The Serum Institute of India acknowledged that it will stop producing new doses of Covishield in December 2021 and has underscored rare adverse effects, including TTS, in its package inserts.
These findings underscore ongoing issues regarding vaccination safety, as well as the importance of rigorous monitoring and assessment systems to address public concerns and assure the safety and efficacy of COVID-19 vaccines.
Source: Inputs from various media Sources
